Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06448091 · ClinicalTrials.gov registry record · NA
Trial of Precision Medicine in Emergency Departments
A NA study of Pharmacogenomic Drug Interaction, sponsored by University of Florida.
- Recruiting
- Registry status
- NA
- Development phase
- 1,200
- Enrollment target
- 3
- Study locations
NCT06448091: Recruiting NA study of Pharmacogenomic Drug Interaction, sponsored by University of Florida.
NCT06448091 is a NA study of Pharmacogenomic Drug Interaction that is actively recruiting participants, run by University of Florida. The registered enrollment target is 1,200 participants, above the 452-participant average among 4 other Pharmacogenomic Drug Interaction trials with a reported enrollment target (165% higher). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06448091, a NA study of Pharmacogenomic Drug Interaction, is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,200 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objectives of this study are to (1) test the feasibility of the clinical implementation of preemptive pharmacogenetic (PGx) testing in the emergency department (ED) and (2) determine if PGx testing (with appropriate decision support) decreases ED return visits and hospitalizations. We will conduct a randomized, controlled, pragmatic clinical trial assessing both the real-world effectiveness as well as implementation outcomes using a targeted PGx testing panel in several UF Health EDs.
Primary Outcome
The primary effectiveness outcome for the trial will be ED recidivism between participants assigned to PGx testing (intervention) compared to those assigned to delayed genotyping (usual care) within 6 months. Specifically, the rate of return visits related to their prior medical problem, identified through a matching primary diagnosis code or clinical impression abstracted from the EHR.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Panel-based pharmacogenetic genotyping
Study Locations (3)
Florida
- UF Health Emergency Department - Gainesville
- UF Health Jacksonville Downtown Emergency Department - Jacksonville
- UF Health Jacksonville North Emergency Department - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2025-03-18 |
| Est. Completion | 2029-02-01 |
| Phase | NA |
What NCT06448091 shows while recruiting
NCT06448091 is an interventional study that assigns participants to a tested intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, above the 452-participant average among 4 other Pharmacogenomic Drug Interaction trials with a reported enrollment target (165% higher).
The record links to 1 condition, with Pharmacogenomic Drug Interaction appearing as the primary indexed condition, and to 1 intervention - of which Panel-based pharmacogenetic genotyping is the first listed.
NCT06448091 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06448091 about?
NCT06448091 is a clinical study titled "Trial of Precision Medicine in Emergency Departments". The objectives of this study are to (1) test the feasibility of the clinical implementation of preemptive pharmacogenetic (PGx) testing in the emergency department (ED) and (2) determine if PGx testing (with appropriate decision support) decreases ED return visits and hospitalizations. We will condu...
What is the current status of trial NCT06448091?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,200 participants. The study started on 2025-03-18. Estimated completion is 2029-02-01.
What conditions does trial NCT06448091 study?
This clinical trial studies the following conditions: Pharmacogenomic Drug Interaction.
What interventions are being tested in trial NCT06448091?
The interventions under investigation include: Panel-based pharmacogenetic genotyping (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06448091?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06448091 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacogenomic Drug Interaction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Geriatric Emergency Department Pharmacologic Harm Prevention Project
RECRUITING · NA
-
Oral Contraceptive Pill (OCP) Pharmacogenomics
RECRUITING · Phase 4
-
Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:
RECRUITING · Phase 2
-
Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI